⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies
globenewswire.com
META
JNJ
PFE
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
globenewswire.com
JNJ
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Antibody Therapeutics Market worth $597.1 billion by 2035 - Exclusive Report by MarketsandMarkets™
prnewswire.com
ABBV
MRK
BMY
JNJ
AMGN
REGN
AlphaSense Announces AlphaSummit 2026 to Explore the Future of Decision-Grade AI
globenewswire.com
GS
JNJ
CRM
MRK
Form 8-K
sec.gov
JNJ
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
businesswire.com
JNJ
Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region
globenewswire.com
JNJ
CNMD
BSX
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
globenewswire.com
BMY
PFE
AMGN
NVS
MRK
LLY
GILD
AZN
TAK
JNJ
ABBV
CRSP
MOD
ARVN
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
prnewswire.com
JNJ